ZN-d5

DRUG4 trials

Sponsors

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., Zentera Therapeutics HK Limited

Conditions

AL AmyloidosisAcute Myeloid LeukemiaAmyloidosisHealthy VolunteersNon Hodgkin LymphomaNon-Hodgkin Lymphoma

Phase 1

Phase 1 First in Human Study of ZN-d5 as a Single Agent

CompletedNCT04500587

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Acute Myeloid Leukemia, Non Hodgkin Lymphoma

Start: 2020-10-13End: 2023-12-12Updated: 2024-09-19

A Food Effect Study of ZN-d5 in Healthy Female Volunteers

CompletedNCT04854174

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Healthy Volunteers

Start: 2021-06-13End: 2021-07-05Updated: 2024-09-19

A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma

TerminatedNCT05127811

Zentera Therapeutics HK LimitedNon-Hodgkin Lymphoma

Start: 2021-10-21End: 2023-05-26Updated: 2023-06-02

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

CompletedNCT05199337

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.AL Amyloidosis, Amyloidosis

Start: 2021-11-30End: 2024-02-14Updated: 2024-09-19

Related Papers

AL Amyloidosis: Current Treatment and Outcomes.

2025-03-032 citations

PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS

HemaSphere2023-08-011 citations

A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

Blood2022-11-151 citations